KR102346228B1 - 보체 활성의 조절 - Google Patents

보체 활성의 조절 Download PDF

Info

Publication number
KR102346228B1
KR102346228B1 KR1020197014115A KR20197014115A KR102346228B1 KR 102346228 B1 KR102346228 B1 KR 102346228B1 KR 1020197014115 A KR1020197014115 A KR 1020197014115A KR 20197014115 A KR20197014115 A KR 20197014115A KR 102346228 B1 KR102346228 B1 KR 102346228B1
Authority
KR
South Korea
Prior art keywords
polypeptide
polypeptides
complement
acid
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020197014115A
Other languages
English (en)
Korean (ko)
Other versions
KR20190057420A (ko
Inventor
미쉘 데니스 호아르티
켁티 아쇼크 담나스카르
다니엘 엘바움
크리스트퍼 조지프슨
켈리 크로닌 라슨
중 마
나탄 에제키엘 님스
알론소 리카르도
캐슬린 세이브
궈-칭 탕
더글라스 에이. 트레코
자오린 왕
핑 예
훙 정
사라 재클린 펄머터
로버트 폴 해머
Original Assignee
라 파마슈티컬스 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54834568&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR102346228(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 라 파마슈티컬스 인코포레이티드 filed Critical 라 파마슈티컬스 인코포레이티드
Priority to KR1020217042686A priority Critical patent/KR102503319B1/ko
Publication of KR20190057420A publication Critical patent/KR20190057420A/ko
Application granted granted Critical
Publication of KR102346228B1 publication Critical patent/KR102346228B1/ko
Assigned to 유씨비 홀딩스 인코포레이티드 reassignment 유씨비 홀딩스 인코포레이티드 권리의 전부이전등록 Assignors: 라 파마슈티컬스 인코포레이티드
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Ophthalmology & Optometry (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020197014115A 2014-06-12 2015-06-12 보체 활성의 조절 Active KR102346228B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020217042686A KR102503319B1 (ko) 2014-06-12 2015-06-12 보체 활성의 조절

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201462011368P 2014-06-12 2014-06-12
US62/011,368 2014-06-12
US201462077460P 2014-11-10 2014-11-10
US62/077,460 2014-11-10
US201562108772P 2015-01-28 2015-01-28
US62/108,772 2015-01-28
PCT/US2015/035473 WO2015191951A2 (en) 2014-06-12 2015-06-12 Modulation of complement activity
KR1020167034788A KR101981532B1 (ko) 2014-06-12 2015-06-12 보체 활성의 조절

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020167034788A Division KR101981532B1 (ko) 2014-06-12 2015-06-12 보체 활성의 조절

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020217042686A Division KR102503319B1 (ko) 2014-06-12 2015-06-12 보체 활성의 조절

Publications (2)

Publication Number Publication Date
KR20190057420A KR20190057420A (ko) 2019-05-28
KR102346228B1 true KR102346228B1 (ko) 2022-01-04

Family

ID=54834568

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020197014115A Active KR102346228B1 (ko) 2014-06-12 2015-06-12 보체 활성의 조절
KR1020167034788A Active KR101981532B1 (ko) 2014-06-12 2015-06-12 보체 활성의 조절
KR1020217042686A Active KR102503319B1 (ko) 2014-06-12 2015-06-12 보체 활성의 조절

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020167034788A Active KR101981532B1 (ko) 2014-06-12 2015-06-12 보체 활성의 조절
KR1020217042686A Active KR102503319B1 (ko) 2014-06-12 2015-06-12 보체 활성의 조절

Country Status (31)

Country Link
US (7) US10106579B2 (https=)
EP (4) EP3973994A1 (https=)
JP (4) JP6432954B2 (https=)
KR (3) KR102346228B1 (https=)
CN (3) CN111187338B (https=)
AP (1) AP2016009612A0 (https=)
AU (3) AU2015274482B2 (https=)
BR (3) BR112016029076B1 (https=)
CA (3) CA3174909A1 (https=)
CY (3) CY1122227T1 (https=)
DK (2) DK3154561T3 (https=)
ES (2) ES2895029T3 (https=)
FI (1) FIC20240015I1 (https=)
FR (1) FR24C1022I2 (https=)
HR (2) HRP20191763T1 (https=)
HU (3) HUE055931T2 (https=)
IL (3) IL249093B (https=)
LT (3) LT3154561T (https=)
MX (2) MX2016016449A (https=)
NL (1) NL301275I2 (https=)
NO (1) NO2024023I1 (https=)
NZ (1) NZ727420A (https=)
PL (2) PL3154561T3 (https=)
PT (2) PT3628680T (https=)
RS (2) RS62428B1 (https=)
RU (1) RU2670988C2 (https=)
SG (1) SG11201610222UA (https=)
SI (2) SI3154561T1 (https=)
SM (2) SMT202100588T1 (https=)
WO (1) WO2015191951A2 (https=)
ZA (3) ZA201706379B (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3973994A1 (en) 2014-06-12 2022-03-30 RA Pharmaceuticals, Inc. Modulation of complement activity
US9937222B2 (en) 2015-01-28 2018-04-10 Ra Pharmaceuticals, Inc. Modulators of complement activity
RU2733720C2 (ru) 2015-12-16 2020-10-06 Ра Фармасьютикалз, Инк. Модуляторы активности комплемента
WO2017189837A1 (en) * 2016-04-29 2017-11-02 The Trustees Of The University Of Pennsylvania Protein kinase rna-like endoplasmic reticulum kinase (perk) inhibitors for prevention and/or treatment of lung injury and/or inflammation
KR20190093196A (ko) 2016-12-07 2019-08-08 라 파마슈티컬스 인코포레이티드 보체 활성의 조절인자
WO2019246405A1 (en) 2018-06-21 2019-12-26 Merck Sharp & Dohme Corp. Cyclic polypeptides for pcsk9 inhibition
IL279363B2 (en) 2018-06-21 2025-12-01 Merck Sharp & Dohme Pcsk9 antagonist compounds
EP3810177B1 (en) * 2018-06-21 2024-12-04 Ra Pharmaceuticals, Inc. Cyclic polypeptides for pcsk9 inhibition
WO2019246386A1 (en) 2018-06-21 2019-12-26 Ra Pharmaceuticals Inc. Cyclic polypeptides for pcsk9 inhibition
EP3870221A1 (en) 2018-10-22 2021-09-01 RA Pharmaceuticals, Inc. Neurological disease treatment with zilucoplan
TW202100179A (zh) 2019-03-08 2021-01-01 美商Ｒａ製藥公司 補體活性之調節劑
SG11202109837SA (en) * 2019-04-24 2021-10-28 Ra Pharmaceuticals Inc Compositions and methods for modulating complement activity
JP2022535411A (ja) 2019-06-04 2022-08-08 ラ ファーマシューティカルズ インコーポレイテッド 補体阻害剤による炎症性疾患治療
CA3150594A1 (en) 2019-09-12 2021-03-18 Ra Pharmaceuticals, Inc. Neurological disease treatment with complement inhibitors
EP4076492A4 (en) 2019-12-20 2024-01-17 Merck Sharp & Dohme LLC PCSK9 ANTAGONIST COMPOUNDS
BR112022010742A2 (pt) 2019-12-26 2022-08-16 Eisai R&D Man Co Ltd Composição farmacêutica contendo ácido ribonucleico de fita dupla que inibe a expressão de c5 complementar
US11932705B2 (en) 2020-12-18 2024-03-19 Merck Sharp & Dohme Llc Cyclic polypeptides for PCSK9 inhibition
CA3204051A1 (en) 2021-01-20 2022-07-28 Brian Lian Compositions and methods for the treatment of metabolic and liver disorders
WO2022177635A2 (en) * 2021-02-22 2022-08-25 Ra Pharmaceuticals, Inc. Compositions and methods for microbial disease treatment
JP7642830B2 (ja) 2021-09-15 2025-03-10 バイキング・セラピューティクス・インコーポレイテッド 代謝及び肝臓障害の処置のための組成物及び方法
WO2023215294A1 (en) * 2022-05-02 2023-11-09 The Board Of Trustees Of The Leland Stanford Junior University Complement pathway inhibition for wound healing
WO2024039636A1 (en) * 2022-08-16 2024-02-22 Ps Therapy, Inc. Methods of use for disulfiram and metabolites thereof
EP4687881A2 (en) * 2023-03-31 2026-02-11 Flexsys IP Holdings, LLC Heteroaryl antidegradants

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090054623A1 (en) * 2004-12-17 2009-02-26 Neose Technologies, Inc. Lipo-Conjugation of Peptides
WO2013037267A1 (zh) * 2011-09-14 2013-03-21 深圳翰宇药业股份有限公司 利拉鲁肽变构体及其缀合物
US20130121917A1 (en) 2010-03-12 2013-05-16 Lawrence Berkeley National Laboratory Lipid-Peptide-Polymer Conjugates and Nanoparticles Thereof

Family Cites Families (113)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4271068A (en) 1968-05-10 1981-06-02 Ciba-Geigy Corporation Process for the manufacture of cystine-containing peptides
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4033940A (en) 1975-11-12 1977-07-05 Armour Pharmaceutical Company Cyclization of peptides
US4216141A (en) 1978-07-19 1980-08-05 The Salk Institute For Biological Studies Method for cyclization of peptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
NZ199722A (en) 1981-02-25 1985-12-13 Genentech Inc Dna transfer vector for expression of exogenous polypeptide in yeast;transformed yeast strain
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US6309669B1 (en) * 1984-03-16 2001-10-30 The United States Of America As Represented By The Secretary Of The Army Therapeutic treatment and prevention of infections with a bioactive materials encapsulated within a biodegradable-biocompatible polymeric matrix
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US5371109A (en) 1986-07-01 1994-12-06 Drilletten Ab Controlled release composition for a biologically active material dissolved or dispersed in an L2-phase
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
FR2641081A1 (https=) * 1988-12-23 1990-06-29 Medgenix Group
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
AU638762B2 (en) 1989-10-05 1993-07-08 Optein Inc Cell-free synthesis and isolation of novel genes and polypeptides
US5585353A (en) 1990-02-02 1996-12-17 The Rockefeller University Antibiotic peptides containing D-amino acids
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US5766897A (en) 1990-06-21 1998-06-16 Incyte Pharmaceuticals, Inc. Cysteine-pegylated proteins
US5843701A (en) 1990-08-02 1998-12-01 Nexstar Pharmaceticals, Inc. Systematic polypeptide evolution by reverse translation
US5270170A (en) 1991-10-16 1993-12-14 Affymax Technologies N.V. Peptide library and screening method
ATE207080T1 (de) 1991-11-25 2001-11-15 Enzon Inc Multivalente antigen-bindende proteine
AU684510B2 (en) 1993-05-28 1997-12-18 Chiron Corporation Method for selection of biologically active peptide sequences
PT710243E (pt) 1993-06-29 2000-11-30 Ferring Bv Sintese melhorada de peptidos ciclicos.
US6074642A (en) 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US6037453A (en) * 1995-03-15 2000-03-14 Genentech, Inc. Immunoglobulin variants
US5834318A (en) 1995-05-10 1998-11-10 Bayer Corporation Screening of combinatorial peptide libraries for selection of peptide ligand useful in affinity purification of target proteins
US5912014A (en) 1996-03-15 1999-06-15 Unigene Laboratories, Inc. Oral salmon calcitonin pharmaceutical products
US6720472B2 (en) 1996-07-12 2004-04-13 University Of Medicine And Dentistry Of New Jersey HMGI proteins in cancer and obesity
US6268343B1 (en) 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
US6348584B1 (en) 1996-10-17 2002-02-19 John Edward Hodgson Fibronectin binding protein compounds
DE69730157T2 (de) 1996-10-17 2005-07-28 Mitsubishi Chemical Corp. Molekül, welches genotyp und phänotyp zusammenführt und dessen anwendungen
US5922680A (en) 1996-10-23 1999-07-13 Ferring, B.V. Stabilized composition for oral administration of peptides
US6261804B1 (en) 1997-01-21 2001-07-17 The General Hospital Corporation Selection of proteins using RNA-protein fusions
ATE332368T1 (de) 1997-01-21 2006-07-15 Gen Hospital Corp Selektion von proteinen mittels rns-protein fusionen
US5990237A (en) 1997-05-21 1999-11-23 Shearwater Polymers, Inc. Poly(ethylene glycol) aldehyde hydrates and related polymers and applications in modifying amines
EP1958962A3 (en) 1997-06-12 2013-05-01 Novartis International Pharmaceutical Ltd. Artificial antibody polypeptides
EP0896001A1 (en) 1997-08-08 1999-02-10 Daicel Chemical Industries, Ltd. Method for preparing oxytocin antagoniste derivatives, intermediates for the preparation of oxytocin antagonist derivatives and method for preparing the intermediates
US6429301B1 (en) 1998-04-17 2002-08-06 Whitehead Institute For Biomedical Research Use of a ribozyme to join nucleic acids and peptides
IL140930A0 (en) 1998-08-07 2002-02-10 Emisphere Tech Inc Compounds and compositions for delivering active agents
WO2000018895A1 (en) * 1998-09-25 2000-04-06 The Children's Medical Center Corporation Short peptides which selectively modulate the activity of protein kinases
AU1705100A (en) 1998-10-09 2000-05-01 Musc Foundation For Research Development Blocking factor b to treat complement-mediated immune disease
US6962781B1 (en) 2000-05-19 2005-11-08 Proteonova, Inc. In vitro evolution of nucleic acids and encoded polypeptide
US7244701B2 (en) 2000-06-16 2007-07-17 Zealand Phama A/S Diuretic peptide conjugate
AU2003228269A1 (en) * 2002-03-01 2003-09-16 Mds Proteomics Inc. Phosphorylated proteins and uses related thereto
WO2004035624A2 (en) * 2002-10-14 2004-04-29 Novo Nordisk A/S Glucagon - like peptide - 2 variants
AU2003298650B2 (en) * 2002-11-15 2010-03-11 Musc Foundation For Research Development Complement receptor 2 targeted complement modulators
EP1961416B1 (en) * 2003-05-05 2013-01-23 Probiodrug AG Use of inhibitors of glutaminyl cyclase for treating psoriasis, rheumatoid arthritis or atherosclerosis.
EP2266606B1 (en) 2003-05-15 2014-09-10 Genentech, Inc. Methods and compositions for the prevention and treatment of sepsis
CA2579635A1 (en) * 2003-09-10 2005-03-17 Baxter International Inc. Peptides that inhibit complement activation
JP4994039B2 (ja) 2003-11-26 2012-08-08 スパーナス ファーマシューティカルズ インコーポレイテッド 脂溶性または疎水性化合物の送達に有用なミセル系
US7803931B2 (en) 2004-02-12 2010-09-28 Archemix Corp. Aptamer therapeutics useful in the treatment of complement-related disorders
US20060027059A1 (en) 2004-08-09 2006-02-09 Chih-Ching Hsien Extendable handle device
WO2006078161A1 (en) 2005-01-24 2006-07-27 Pepscan Systems B.V. Binding compounds, immunogenic compounds and peptidomimetics
CA2610502A1 (en) 2005-03-29 2006-10-05 Cardax Pharmaceuticals, Inc. Reduction in complement activation and inflammation during tissue injury by carotenoids, carotenoid analogs, or derivatives thereof
WO2006128006A1 (en) 2005-05-26 2006-11-30 The Regents Of The University Of Colorado Inhibition of the alternative complement pathway for treatment of traumatic brain injury, spinal cord injury and related conditions
EP1888031B1 (en) 2005-06-06 2013-01-23 Camurus Ab Glp-1 analogue formulations
SG10201804008UA (en) 2005-11-04 2018-06-28 Genentech Inc Use of complement pathway inhibitors to treat ocular diseases
US20090220508A1 (en) 2006-03-15 2009-09-03 Alexion Pharmaceuticals, Inc. Treatment Of Paroxysmal Nocturnal Hemoglobinuria Patients By An Inhibitor Of Complement
EP1876183A1 (en) * 2006-07-04 2008-01-09 Technische Universität München Minimized small peptides with high affinity for factor VIII and factor VIII-like proteins
EP2073898A1 (en) 2006-10-10 2009-07-01 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Complement inhibition for improved nerve regeneration
US7736860B2 (en) 2006-11-09 2010-06-15 Univeristy Of Massachusetts Methods of identifying compounds for the treatment of sterile inflammation
US20100092493A1 (en) 2007-03-06 2010-04-15 Novo Nordisk A/S Modulation of Complement System Activation for Treatment of Bleeding-Related Inflammation
AU2008228247A1 (en) * 2007-03-22 2008-09-25 Novartis Ag C5 antigens and uses thereof
US20100015139A1 (en) 2008-07-10 2010-01-21 Rekha Bansal METHOD OF INHIBITING COMPLEMENT ACTIVATION WITH FACTOR Ba SPECIFIC ANTIBODIES AND USE THEREOF
CA2680833A1 (en) 2007-04-30 2008-11-13 Alcon Research, Ltd. Treatment of age-related macular degeneration using inhibitors of complement factor d
RU2473563C2 (ru) 2007-06-07 2013-01-27 Дженентек, Инк. АНТИТЕЛА ПРОТИВ C3b И СПОСОБЫ ПРОФИЛАКТИКИ И ЛЕЧЕНИЯ СВЯЗАННЫХ С КОМПЛЕМЕНТОМ НАРУШЕНИЙ
US20110142837A1 (en) 2007-07-20 2011-06-16 Trustees Of The University Of Pennsylvania Method Of Treating Acute Respiratory Distress Syndrome
BRPI0817524A2 (pt) 2007-10-02 2017-05-02 Potentia Pharmaceuticals Inc liberação prolongada de análogos de compstatina provenientes de géis
WO2009067191A2 (en) 2007-11-16 2009-05-28 The General Hospital Corporation Methods and compositions for the treatment of hepatitis c virus (hcv) infection
US20110190221A1 (en) 2008-03-28 2011-08-04 Apellis Ag Modulation and repletion/enhancement of the complement system for treatment of trauma
EP2324048A2 (en) 2008-07-30 2011-05-25 Cosmix Therapeutics Llc Peptide therapeutics that bind vegf and methods of use thereof
PY09026846A (es) * 2008-08-05 2015-09-01 Novartis Ag Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento c5
US20110172126A1 (en) 2008-09-03 2011-07-14 Xenome Ltd Libraries of peptide conjugates and methods for making them
CA2742802C (en) 2008-11-10 2019-11-26 Alexion Pharmaceuticals, Inc. Methods and compositions for treating complement-associated disorders
AU2009230735B1 (en) 2009-01-08 2010-01-21 Shane Ramodien Electronic equipment housing
DK2488203T3 (en) 2009-10-16 2017-03-13 Omeros Corp METHODS OF TREATING DISSEMINATED INTRAVASCULAR COAGULATION BY INHIBITION OF MASP-2 DEPENDENT COMPLEMENT ACTIVATION
CA2795311A1 (en) * 2009-11-05 2011-05-12 Taligen Therapeutics, Inc. Treatment of paroxysmal nocturnal hemoglobinuria, hemolytic anemias and disease states involving intravascular and extravascular hemolysis
JP6006118B2 (ja) 2009-12-16 2016-10-12 ノヴォ ノルディスク アー／エス Ｇｌｐ−１アナログ及び誘導体
US9172511B2 (en) 2009-12-24 2015-10-27 Samsung Electronics Co., Ltd. Apparatus and method of communicating automatic repeat request (ARQ) feedback in a wireless communication network
US9358266B2 (en) 2010-02-25 2016-06-07 The Trustees Of The University Of Pennsylvania Treatment of sepsis using complement inhibitors
WO2011139343A2 (en) * 2010-04-28 2011-11-10 Wu Nian Amino acid linked peg-lipid conjugates
EP2563359A1 (en) 2010-04-30 2013-03-06 Allergan, Inc. Novel treatment for age related macular degeneration and ocular ischemic disease associated with complement activation by targeting 5-lipoxygenase
TW201241008A (en) * 2010-10-01 2012-10-16 Alexion Pharma Inc Polypeptides that bind to human complement component C5
PH12013501865A1 (en) * 2011-03-16 2014-01-06 Amgen Inc Potent and selective inhibitors of nav1.3 and nav1.7
BR112013025917A2 (pt) 2011-04-08 2016-12-20 Omeros Corp uso de um anticorpo masp-2 ou fragmento do mesmo que inibe ativação de complemento dependente de masp-2
WO2012162215A1 (en) 2011-05-20 2012-11-29 The Trustees Of The University Of Pennsylvania Promotion of fracture healing using complement inhibitors
WO2012174055A1 (en) 2011-06-13 2012-12-20 The Trustees Of The University Of Pennsylvania Wound healing using complement inhibitors
US20140296147A1 (en) * 2011-10-06 2014-10-02 The Medicines Company Methods of treating or preventing blood loss during surgery using the serine protease inhibitor mdco-2010
EP3511339B1 (en) * 2012-02-20 2025-04-09 IPC Research, LLC Polypeptides binding to human complement c5
US20130246083A1 (en) 2012-03-16 2013-09-19 Alexion Pharmaceuticals, Inc. Methods of distributing complement-inhibiting drugs to patients receiving a complement inhibitor
WO2013172954A1 (en) 2012-05-17 2013-11-21 Ra Pharmaceuticals, Inc Peptide and peptidomimetic inhibitors
US9579360B2 (en) 2012-06-20 2017-02-28 The Trustees Of The University Of Pennsylvania Methods of treating or preventing periodontitis and diseases associated with periodontitis
US20130345257A1 (en) 2012-06-26 2013-12-26 The Regents Of The University Of California Composition for lupus nephritis and methods of making and using the same
WO2014078622A1 (en) 2012-11-15 2014-05-22 The Brigham And Women's Hospital, Inc. Method and system for diagnosing and treating preeclampsia
US9700633B2 (en) * 2013-01-28 2017-07-11 Jenkem Technology Co., Ltd., Tianjin Branch Conjugates of water soluble polymer-amino acid oligopeptide-drug, preparation method and use thereof
GB201301632D0 (en) * 2013-01-30 2013-03-13 Imp Innovations Complement System
US20140234275A1 (en) 2013-02-15 2014-08-21 Jason Williams Method for treating als via the increased production of factor h
US20150057342A1 (en) 2013-08-21 2015-02-26 Cannabics Pharmaceuticals Inc Compositions for combined immediate and sustained release of cannabinoids, methods of manufacture and use thereof
CA2940319A1 (en) 2014-03-20 2015-09-24 Inflarx Gmbh Inhibitors of c5a for the treatment of viral pneumonia
EP3973994A1 (en) 2014-06-12 2022-03-30 RA Pharmaceuticals, Inc. Modulation of complement activity
US20160168237A1 (en) 2014-12-12 2016-06-16 Alexion Pharmaceuticals, Inc. Method for treating a complement mediated disorder caused by an infectious agent in a patient
EP3142656B1 (en) 2015-01-21 2018-10-17 Pacira Pharmaceuticals, Inc. Multivesicular liposome formulations of tranexamic acid
US9937222B2 (en) * 2015-01-28 2018-04-10 Ra Pharmaceuticals, Inc. Modulators of complement activity
WO2017035362A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Use of complement pathway inhibitor compounds to mitigate adoptive t-cell therapy associated adverse immune responses
RU2733720C2 (ru) 2015-12-16 2020-10-06 Ра Фармасьютикалз, Инк. Модуляторы активности комплемента
KR20190093196A (ko) 2016-12-07 2019-08-08 라 파마슈티컬스 인코포레이티드 보체 활성의 조절인자
TWI826364B (zh) 2017-04-03 2023-12-21 德商因夫萊亞斯有限公司 活性抑制劑於發炎性疾病之治療
EP3682016A4 (en) 2017-09-11 2021-06-02 RA Pharmaceuticals, Inc. FORMULATIONS FOR THE ADMINISTRATION OF COMPOUNDS
CN111683672A (zh) 2017-12-04 2020-09-18 Ra制药公司 补体活性调节剂
TW202100179A (zh) 2019-03-08 2021-01-01 美商Ｒａ製藥公司 補體活性之調節劑
SG11202109837SA (en) 2019-04-24 2021-10-28 Ra Pharmaceuticals Inc Compositions and methods for modulating complement activity

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090054623A1 (en) * 2004-12-17 2009-02-26 Neose Technologies, Inc. Lipo-Conjugation of Peptides
US20130121917A1 (en) 2010-03-12 2013-05-16 Lawrence Berkeley National Laboratory Lipid-Peptide-Polymer Conjugates and Nanoparticles Thereof
WO2013037267A1 (zh) * 2011-09-14 2013-03-21 深圳翰宇药业股份有限公司 利拉鲁肽变构体及其缀合物

Also Published As

Publication number Publication date
EP3154561A4 (en) 2018-04-18
SI3628680T1 (sl) 2021-12-31
CN119236050A (zh) 2025-01-03
US10435438B2 (en) 2019-10-08
FR24C1022I2 (fr) 2025-05-23
JP2022034057A (ja) 2022-03-02
DK3628680T3 (da) 2021-10-11
KR101981532B1 (ko) 2019-09-02
NL301275I2 (nl) 2024-06-20
CN111187338A (zh) 2020-05-22
US11014965B2 (en) 2021-05-25
US20210246167A1 (en) 2021-08-12
AU2021204313A1 (en) 2021-07-22
FR24C1022I1 (fr) 2024-07-19
NZ727420A (en) 2018-06-29
AU2019200828A1 (en) 2019-02-28
LT3154561T (lt) 2019-11-25
ZA202001859B (en) 2021-04-28
KR20190057420A (ko) 2019-05-28
CA2949985A1 (en) 2015-12-17
US20200123202A1 (en) 2020-04-23
PL3628680T3 (pl) 2022-01-10
AU2015274482B2 (en) 2018-11-08
RS59353B1 (sr) 2019-10-31
US10106579B2 (en) 2018-10-23
IL249093A0 (en) 2017-01-31
RU2018136750A (ru) 2018-11-06
EP3628680A1 (en) 2020-04-01
SMT202100588T1 (it) 2021-11-12
JP6770043B2 (ja) 2020-10-14
HUE045646T2 (hu) 2020-01-28
EP3628680B1 (en) 2021-09-08
EP3973994A1 (en) 2022-03-30
BR112016029076B1 (pt) 2024-02-15
RU2670988C2 (ru) 2018-10-29
RU2016147080A3 (https=) 2018-06-01
CY2024015I1 (el) 2024-12-13
CY1124595T1 (el) 2022-07-22
IL273746B (en) 2021-03-25
SG11201610222UA (en) 2017-01-27
RU2018136750A3 (https=) 2021-10-19
US11965040B2 (en) 2024-04-23
KR20220002727A (ko) 2022-01-06
BR112016029076A2 (pt) 2018-06-05
LTPA2024514I1 (https=) 2024-06-10
EP3154561A2 (en) 2017-04-19
RU2016147080A (ru) 2018-06-01
US20190119328A1 (en) 2019-04-25
IL281264A (en) 2021-04-29
HUE055931T2 (hu) 2022-01-28
CY1122227T1 (el) 2020-11-25
LTC3154561I2 (https=) 2025-11-10
EP3154561B1 (en) 2019-09-04
JP2019048834A (ja) 2019-03-28
IL273746A (en) 2020-05-31
NO2024023I1 (no) 2024-05-24
HRP20211561T8 (hr) 2022-03-04
US11535650B1 (en) 2022-12-27
US10208089B2 (en) 2019-02-19
AP2016009612A0 (en) 2016-12-31
BR122023024819A2 (pt) 2023-12-26
US10562934B2 (en) 2020-02-18
EP4223317A2 (en) 2023-08-09
ZA201900497B (en) 2019-10-30
RS62428B1 (sr) 2021-11-30
CA3241273A1 (en) 2015-12-17
PL3154561T3 (pl) 2019-12-31
JP7002597B2 (ja) 2022-02-04
IL281264B (en) 2022-05-01
PT3628680T (pt) 2021-10-07
HUS2400015I1 (hu) 2024-06-28
ES2750556T3 (es) 2020-03-26
HRP20211561T1 (hr) 2021-12-24
BR122021025449B1 (pt) 2024-02-15
HRP20191763T1 (hr) 2019-12-27
ES2895029T3 (es) 2022-02-17
MX2016016449A (es) 2017-08-24
JP7454545B2 (ja) 2024-03-22
FIC20240015I1 (fi) 2024-05-28
CA2949985C (en) 2023-10-17
MX2021009309A (es) 2021-10-26
BR112016029076A8 (pt) 2022-02-08
WO2015191951A3 (en) 2016-03-03
US20200002380A1 (en) 2020-01-02
CN106456701B (zh) 2020-01-07
IL249093B (en) 2020-05-31
WO2015191951A2 (en) 2015-12-17
KR20170003993A (ko) 2017-01-10
ZA201706379B (en) 2018-12-19
AU2019200828B2 (en) 2021-04-08
NZ736573A (en) 2024-03-22
KR102503319B1 (ko) 2023-02-28
JP2020128417A (ja) 2020-08-27
LT3628680T (lt) 2021-11-25
US20180371019A1 (en) 2018-12-27
NZ761610A (en) 2024-03-22
CN111187338B (zh) 2024-08-02
JP6432954B2 (ja) 2018-12-05
CA3174909A1 (en) 2015-12-17
SI3154561T1 (sl) 2019-11-29
JP2017523232A (ja) 2017-08-17
EP4223317A3 (en) 2023-09-27
DK3154561T3 (da) 2019-10-07
CY2024015I2 (el) 2024-12-13
US20170137468A1 (en) 2017-05-18
AU2021204313B2 (en) 2024-01-04
AU2015274482A1 (en) 2017-01-12
PT3154561T (pt) 2019-10-25
CN106456701A (zh) 2017-02-22
SMT201900568T1 (it) 2019-11-13

Similar Documents

Publication Publication Date Title
US11535650B1 (en) Modulation of complement activity
US12239684B2 (en) Modulators of complement activity
RU2778514C2 (ru) Модуляция активности комплемента
HK40073624A (en) Modulators of complement activity
HK40072986A (en) Modulation of complement activity

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

X091 Application refused [patent]
AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

PX0701 Decision of registration after re-examination

St.27 status event code: A-3-4-F10-F13-rex-PX0701

X701 Decision to grant (after re-examination)
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R11-asn-PN2301

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R14-asn-PN2301

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 5

G19 Pte not granted

Free format text: ST27 STATUS EVENT CODE: A-4-4-G10-G19-TEX-PE0602 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0602 Decision to reject extension of term of patent right by permit, etc.

St.27 status event code: A-4-4-G10-G19-tex-PE0602